... Sotorasib is an irreversible KRAS G12C inhibitor that has been granted breakthrough therapy designation based on the findings of the ...

YouTube-VJOncology

Sotorasib is approved in the United States to treat KRAS p.G12C–mutated non–small-cell lung cancer. Its efficacy and safety in KRAS p.

Facebook-The New England Journal of Medicine

LBA10 - Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study ...

YouTube-European Society for Medical Oncology (ESMO)

... sotorasib (AMG 510) in KRAS p.G12C mutated non-small cell lung cancer (NSCLC). Sotorasib is a first-in-class irreversible inhibitor of KRAS ...

YouTube-VJOncology

Dr. Filippo Pietrantonio reports on key results from ESMO Congress 2023 on LBA10 - Sotorasib plus panitumumab versus standard-of-care for ...

YouTube-European Society for Medical Oncology (ESMO)

Dr Melissa Johnson presents the primary analysis of the phase 3 CodeBreaK 200 trial comparing sotorasib versus docetaxel in previously ...

ecancer

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, provides an overview of the Phase III CodeBreaK 200 trial (NCT04303780) ...

YouTube-VJOncology

In patients with metastatic colorectal cancer with KRAS G12C mutation, combining a KRAS G12C inhibitor with an EGFR inhibitor may be an ...

YouTube-NEJM Group

Burst Edition: FDA approvals of Lumakras (sotorasib) for patients with KRAS G12C ... 36 views · 1 month ago FDA Drug Information Soundcast ...

YouTube-U.S. Food and Drug Administration

Ferdinandos Skoulidis presents an update from the CodeBreaK 100 trial of sotorasib in previously treated patients with non-small-cell lung ...

YouTube-Medicine Matters oncology

Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, presented the results of the Phase III CodeBreaK 300 ...

VJOncology

Melissa Johnson provides an overview of the CodeBreaK 200 study pitting sotorasib against docetaxel in patients who have received prior ...

YouTube-Medicine Matters oncology

Sotorasib is a KRASG12C inhibitor which causes known drug-drug interactions that may lead to treatment inefficacy or serious side effects ...

YouTube-VJOncology

Drs. Ibiayi Dagogo-Jack, Joshua Reuss, Natalie Vokes, and Kathryn Arbour discuss three hypothetical cases of suspected cancer, from staging ...

YouTube-GRACE - Global Resource for Advancing Cancer Education

ESMO is Europe's leading medical oncology society, providing a professional network for its members and working with national societies ...

ESMO-European Society for Medical Oncology (ESMO)

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, provides an overview of the Phase III CodeBreaK 200 trial (NCT04303780) ...

YouTube-VJOncology

Andrew Parsons presents the development of a commercial manufacturing process for sotorasib, a first-in-class KRASG12C inhibitor.

YouTube-Drug Hunter

Drs. Ibiayi Dagogo-Jack, Joshua Reuss, Natalie Vokes, and Kathryn Arbour discuss three hypothetical cases of suspected cancer, from staging ...

YouTube-GRACE - Global Resource for Advancing Cancer Education

CodeBreak 300: sotorasib + panitumumab vs. standard-of-care in chemorefractory KRAS G12C mCRC · VJOncology · ESMO 2023 GI Cancer Highlights – ...

YouTube-VJOncology

Highlights on sotorasib plus panitumumab in KRAS G12C-mutated mCRC: The CodeBreak 300 study. 22 Oct 2023. Search. ESMO · Meeting Calendar · OncologyPRO.

OncologyPRO-European Society for Medical Oncology (ESMO)